Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
This grant funds early-stage, highly innovative technology development projects to improve cancer research or clinical care, focusing on proof-of-concept studies with high potential impact in cancer-related fields.
Funder: National Institutes of Health
Due Dates (Anticipated): June 2027 (Full application deadline, projected)
Funding Amounts: Up to $150,000 per award; total program funding estimated at $5.4 million; ~23 awards expected.
Summary: Supports early-stage, highly innovative technology development for cancer research or clinical care, emphasizing proof-of-concept studies.
Description
This opportunity, issued by the National Cancer Institute (NCI) through the Innovative Molecular Analysis Technologies (IMAT) Program, seeks applications for the development of novel technologies to advance basic and clinical cancer research. The focus is on early-stage, proof-of-concept or pilot projects that demonstrate the technical feasibility of new methods, tools, assays, platforms, or instruments. Proposed technologies should exhibit significant innovation and the potential to accelerate or enhance research in cancer biology, early detection, screening, diagnosis, treatment, control, or epidemiology. Areas of interest include, but are not limited to:
- Advanced molecular and cellular analysis platforms
- Multi-omic and spatial profiling methods
- Imaging and sensing technologies
- Immuno-engineering approaches
- Innovations in biospecimen processing, modeling, and quality assessment
All proposed technology development must be directly applicable to cancer research or clinical care.
